Cerner Multum, Inc. "UK Summary of Product Characteristics."
You may report them to the The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. When ethambutol hydrochloride is used in conjunction with other antituberculosis agents for the treatment of disseminated MAC infection, a dosage of 15 mg/kg daily has been recommended by ATS.For maintenance therapy to prevent recurrence of disseminated MAC infection (secondary prophylaxis), the Prevention of Opportunistic Infections Working Group of the US Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) recommends that adults or adolescents receive clarithromycin (500 mg twice daily) or azithromycin (500 mg once daily) in conjunction with ethambutol hydrochloride (15 mg/kg once daily), with or without rifabutin (300 mg once daily).For maintenance therapy to prevent recurrence of disseminated MAC infection (secondary prophylaxis), the USPHS/IDSA recommends that infants and children receive clarithromycin (7. mg/kg [maximum 500 mg] daily) or azithromycin (5 mg/kg [maximum 250 mg] once daily) in conjunction with ethambutol hydrochloride (15 mg/kg [maximum 900 mg] once daily), with or without rifabutin (5 mg/kg [maximum 300 mg] once daily).In patients with impaired renal function, doses and/or frequency of administration of ethambutol hydrochloride should be modified in response to the degree of renal impairment. Medlineplus.gov. O 03. The extent of ocular toxicity appears to be related to the dose and duration of ethambutol therapy. eHealthMe has been monitoring drugs since 2008. Sources include the official FAERS database and social media including user reviews and forum discussions.
The drug should also be used with caution in patients with ocular defects (e.g., cataracts, recurrent ocular inflammatory conditions, diabetic retinopathy) that make visual changes difficult to detect or evaluate; consideration should be given to whether the benefits of ethambutol therapy justify the possible ocular effects in these patients.Ethambutol is contraindicated in patients with optic neuritis unless clinical judgment deems it necessary that the drug be used.Ethambutol is also contraindicated in patients with known hypersensitivity to the drug.The manufacturer states that ethambutol should not be used in children younger than 13 years of age. There is no evidence of cross-resistance between ethambutol and other antituberculosis agents currently available in the US.Approximately 75-80% of an oral dose of ethambutol hydrochloride is rapidly absorbed from the GI tract. Therapeutic Goods Administration (TGA). Teratogenicity has been observed in Neutropenia has been reported in a patient on ethambutol, isoniazid, and rifampicin. The study is created by eHealthMe based on reports (from sources including the FDA) of 21,063 people who take Isoniazid and Ethambutol hydrochloride, and is updated regularly. Ethambutol hydrochloride tablets are not recommended for use in pediatric patients under 13 years of age since safe conditions for use have not been established. Ethambutol hydrochloride is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients). Any changes in the vision should be reported to the doctor.
In patients receiving a daily treatment regimen for the initial phase, the ATS, CDC, and IDSA state that ethambutol usually can be discontinued when in vitro susceptibility tests indicate that the strain of Mycobacterium tuberculosis is susceptible to isoniazid and rifampin.Ethambutol also is considered a first-line agent for use in multiple-drug regimens for the management of patients with drug-resistant pulmonary tuberculosis.Ethambutol is used in conjunction with other antituberculosis agents in the treatment of Mycobacterium avium complex (MAC) infections. In adults who have received previous antituberculosis therapy, the usual dosage recommended by the manufacturer for use in conjunction with other antituberculosis agents is 25 mg/kg daily for 60 days or until bacteriologic smears and cultures become negative, followed by 15 mg/kg daily.The American Thoracic Society (ATS), US Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) recommend that when ethambutol hydrochloride is used in an initial regimen that involves daily administration of antituberculosis agents, adults and children 15 years of age or older weighing 40-55 kg should receive a dosage of 800 mg, those weighing 56-75 kg should receive 1.2 g, and those weighing 76-90 kg should receive 1.6 g. The maximum daily dosage recommended is 1.6 g regardless of weight.If ethambutol hydrochloride is used in an intermittent regimen that involves twice-weekly administration of antituberculosis agents, the ATS, CDC, and IDSA recommend that adults and children 15 years of age or older weighing 40-55 kg should receive a dosage of 2 g, those weighing 56-75 kg should receive 2.8 g, and those weighing 76-90 kg should receive 4 g; the maximum dosage for this regimen is 2.4 g regardless of weight.
The most commonly reported side effects included decreased visual acuity and optic neuritis. Rarely, depending on the degree of impairment, recovery may be delayed for up to 1 year or more, or the effect may be irreversible.